State Street’s Voyager Therapeutics VYGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.77M | Buy |
1,076,422
+128,196
| +14% | +$486K | ﹤0.01% | 3145 |
|
|
2026
Q1 | $3.66M | Buy |
948,226
+11,960
| +1% | +$47.1K | ﹤0.01% | 3080 |
|
|
2025
Q4 | $3.68M | Buy |
936,266
+10,908
| +1% | +$48.2K | ﹤0.01% | 3120 |
|
|
2025
Q3 | $4.32M | Buy |
925,358
+31,438
| +4% | +$114K | ﹤0.01% | 3047 |
|
|
2025
Q2 | $2.78M | Sell |
893,920
-8,832
| -1% | -$28.5K | ﹤0.01% | 3194 |
|
|
2025
Q1 | $3.05M | Buy |
902,752
+1,820
| +0.2% | +$8.5K | ﹤0.01% | 3074 |
|
|
2024
Q4 | $5.11M | Buy |
900,932
+8,189
| +0.9% | +$52.8K | ﹤0.01% | 2967 |
|
|
2024
Q3 | $5.22M | Sell |
892,743
-896,446
| -50% | -$6.52M | ﹤0.01% | 2954 |
|
|
2024
Q2 | $14.2M | Buy |
1,789,189
+40,021
| +2% | +$336K | ﹤0.01% | 2347 |
|
|
2024
Q1 | $16.3M | Buy |
1,749,168
+1,129,356
| +182% | +$9.53M | ﹤0.01% | 2297 |
|
|
2023
Q4 | $5.23M | Buy |
619,812
+37,583
| +6% | +$273K | ﹤0.01% | 2922 |
|
|
2023
Q3 | $4.51M | Buy |
582,229
+37,365
| +7% | +$341K | ﹤0.01% | 2969 |
|
|
2023
Q2 | $6.24M | Buy |
544,864
+450,767
| +479% | +$4.66M | ﹤0.01% | 2892 |
|
|
2023
Q1 | $725K | Buy |
94,097
+5,300
| +6% | +$42.1K | ﹤0.01% | 3628 |
|
|
2022
Q4 | $542K | Hold |
88,797
| – | – | ﹤0.01% | 3746 |
|
|
2022
Q3 | $526K | Hold |
88,797
| – | – | ﹤0.01% | 3759 |
|
|
2022
Q2 | $525K | Sell |
88,797
-4,600
| -5% | -$31.1K | ﹤0.01% | 3811 |
|
|
2022
Q1 | $712K | Buy |
93,397
+8,583
| +10% | +$38.3K | ﹤0.01% | 3914 |
|
|
2021
Q4 | $230K | Hold |
84,814
| – | – | ﹤0.01% | 4285 |
|
|
2021
Q3 | $223K | Hold |
84,814
| – | – | ﹤0.01% | 4320 |
|
|
2021
Q2 | $350K | Sell |
84,814
-405,656
| -83% | -$1.84M | ﹤0.01% | 3992 |
|
|
2021
Q1 | $2.31M | Sell |
490,470
-64,410
| -12% | -$439K | ﹤0.01% | 3377 |
|
|
2020
Q4 | $3.97M | Sell |
554,880
-11,679
| -2% | -$112K | ﹤0.01% | 3074 |
|
|
2020
Q3 | $6.04M | Sell |
566,559
-715,307
| -56% | -$8.4M | ﹤0.01% | 2691 |
|
|
2020
Q2 | $16.2M | Sell |
1,281,866
-87,784
| -6% | -$1.02M | ﹤0.01% | 2151 |
|
|
2020
Q1 | $12.5M | Buy |
1,369,650
+44,002
| +3% | +$505K | ﹤0.01% | 2130 |
|
|
2019
Q4 | $18.5M | Sell |
1,325,648
-85,139
| -6% | -$1.24M | ﹤0.01% | 2194 |
|
|
2019
Q3 | $24.3M | Buy |
1,410,787
+202,283
| +17% | +$4.25M | ﹤0.01% | 1945 |
|
|
2019
Q2 | $32.9M | Buy |
1,208,504
+830,409
| +220% | +$19M | ﹤0.01% | 1759 |
|
|
2019
Q1 | $7.24M | Buy |
378,095
+12,540
| +3% | +$163K | ﹤0.01% | 2596 |
|
|
2018
Q4 | $3.44M | Sell |
365,555
-936,733
| -72% | -$12M | ﹤0.01% | 2890 |
|
|
2018
Q3 | $24.6M | Buy |
1,302,288
+72,376
| +6% | +$1.39M | ﹤0.01% | 2038 |
|
|
2018
Q2 | $24M | Buy |
1,229,912
+430,966
| +54% | +$8.52M | ﹤0.01% | 2003 |
|
|
2018
Q1 | $15M | Buy |
798,946
+566,786
| +244% | +$12.2M | ﹤0.01% | 2234 |
|
|
2017
Q4 | $3.85M | Buy |
232,160
+33,502
| +17% | +$574K | ﹤0.01% | 2911 |
|
|
2017
Q3 | $4.09M | Buy |
198,658
+14,132
| +8% | +$159K | ﹤0.01% | 2893 |
|
|
2017
Q2 | $1.65M | Buy |
184,526
+19,471
| +12% | +$196K | ﹤0.01% | 3216 |
|
|
2017
Q1 | $2.19M | Sell |
165,055
-448
| -0.3% | -$5.44K | ﹤0.01% | 3052 |
|
|
2016
Q4 | $2.11M | Buy |
165,503
+8,257
| +5% | +$106K | ﹤0.01% | 3086 |
|
|
2016
Q3 | $1.89M | Buy |
157,246
+14,635
| +10% | +$198K | ﹤0.01% | 2988 |
|
|
2016
Q2 | $1.56M | Buy |
142,611
+84,906
| +147% | +$1.04M | ﹤0.01% | 3120 |
|
|
2016
Q1 | $502K | Buy |
57,705
+11,900
| +26% | +$135K | ﹤0.01% | 3352 |
|
|
2015
Q4 | $1M | Buy |
+45,805
| New | +$1.06M | ﹤0.01% | 3207 |
|
Other funds holding VYGR
AC
VPC
OM
State Street's VYGR Position: Q2 2026 in Review
State Street increased its Voyager Therapeutics (VYGR) stake by 14% in Q2 2026, buying an estimated $486K and bringing the position to 1,076,422 shares worth $3.77M. The position accounts for ﹤0.01% of the portfolio, ranked #3145.
State Street first reported a position in VYGR in Q4 2015 and has held it in 43 quarters since. The position peaked at $32.9M in Q2 2019. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.
- State Street held 1,076,422 shares of Voyager Therapeutics worth $3.77M as of Q2 2026.
- State Street bought 128,196 Voyager Therapeutics shares in Q2 2026, an estimated $486K.
- Voyager Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3145 holding.
- State Street first reported a position in Voyager Therapeutics in Q4 2015 and has held it in 43 quarters since.
- State Street's Voyager Therapeutics position peaked at $32.9M in Q2 2019.
- 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.
Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.